Therefore, Hsp–Cu(II) improved glucose metabolic disorders and alleviated T2DM by modulating gut microbiota composition, enriching the beneficial bacteria, and promoting the production of SCFAs, reducing the amount of harmful bacteria, suppressing local inflammation, and restoring intestinal barrier integrity. The gene discussed is HSP90B2P; the disease is glucose metabolism disease.